AMSTERDAM – Secarna Pharmaceuticals GmbH & Co. KG, an early stage German firm, is giving a new lease of life to an old European antisense technology which will soon lose patent protection. The Marburg-based firm was formed in 2015, but has flown under the radar until recently. It was among the young contenders setting out their stall at the recent BIO-Europe Spring meeting.